FAP

Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM).

BR103354 is a selective inhibitor of fibroblast activation protein (FAP) with an IC50 of 14 nM against human FAP. It effectively restores levels of phosphorylated ERK and Glut1, reduces non-fasting blood glucose concentrations, and enhances glucose tolerance, while also decreasing hepatic triglyceride content. This compound demonstrates potential in alleviating hepatic steatosis and fibrosis, making it a valuable tool for research into type 2 diabetes and non-alcoholic steatohepatitis.

Simlukafusp alfa is an immunocytokine composed of an antibody targeting fibroblast activation protein α (FAPα) and a variant of interleukin-2 (IL-2) that selectively engages the IL-2 receptor βγ chain. This unique structure enhances the immune response against FAPα-expressing tumors while promoting T-cell activation and proliferation. Simlukafusp alfa is suitable for research applications focused on cancer immunotherapy and the study of tumor microenvironments, particularly in evaluating the efficacy of targeted immune modulation.

NOTA-FAPI-52 is a tumor uptake tracer that targets fibroblast activation protein (FAP). This compound can be radiolabeled for use in positron emission tomography (PET) imaging and other bioimaging methods. NOTA-FAPI-52 is particularly useful in studying diseases characterized by the overexpression of FAP, aiding in the understanding of various tumor environments and potential therapeutic interventions.

L-Proline 4-methoxy-β-naphthylamide hydrochloride primarily targets FAP (Fibroblast Activation Protein) and serves as a potential anti-tumor agent. This compound is utilized in the preparation of FAP-activated anti-tumor compounds, making it relevant in cancer research and therapeutic development. Its unique chemical structure contributes to the exploration of novel strategies for targeting tumor microenvironments.

Ac-Gly-Pro-AFC is a fluorogenic substrate specifically designed to assess fibroblast activation protein (FAP) endopeptidase activity. This compound exhibits high sensitivity and selectivity, making it useful for studying FAP's role in tumor microenvironments and fibrosis. It is applicable in various research domains, including cancer biology and tissue remodeling studies, facilitating the quantification of enzymatic activity in biological samples.

SID 125240931 is a modulator of fluorogen activating proteins (FAPs), primarily targeting the interaction between fluorogens and FAP. This compound is designed to disrupt binding affinity, providing insights into FAP-mediated processes. It has potential applications in cellular imaging and monitoring protein interactions, making it a valuable tool for researchers in cell biology and molecular imaging studies.